Page 4 - Sun Pharma

Pharma shares in focus; GSK, Jubilant, Eris, Gland, Torrent rally up to 8%

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as investors responded positively to strong Q4 results and favourable FY26 outlook

Sun Pharma Q4 preview: Analysts expect 18% jump in profit; check details

Sun Pharma Q4 results date: Sun Pharma is scheduled to announce its fourth quarter results on Thursday, May 22, 2025

Sun Pharma gets USFDA approval for new device to treat skin disease

The company says that the new device is more compact and easier to use than its predecessor

Nifty Pharma drops 2% after Trump reveals plans to lower US drug cost

The US President has predicted that pharmaceutical prices could drop 30 per cent to 80 per cent in America

Stock downfall: The side effects are real, but Sun Pharma stays on its feet

Growth hormone kicks in as India's largest pharma firm's vital signs hold amid generic strain

Sun Pharma stock up 2.15% as US court clears alopecia drug launch

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 million in FY27

Pharma stocks surge as Trump puts 90-day hold on planned tariffs

Nifty Pharma has fallen by 12.8 per cent so far this year, with Natco Pharma and Granules India leading the plunge

Here's why Sun Pharma share price advanced 5% in trade on April 11; details

The rise in the Sun Pharma share price came after a favourable ruling from a US court regarding its planned launch of Leqselvi (deuruxolitinib).

US court clears Sun Pharma to launch Leqselvi for alopecia areata treatment

Sun Pharma is now preparing to launch the drug in US markets after facing legal issues since November 2024

5 pharma stocks that you should stay away from given their tech charts

Technical charts hint that pharma shares such as Cipla, Lupin, Sun Pharma, Zydus Lifesciences and Gland Pharma could slide up to 23% as Trump tariff threat on pharma import looms.

Sun Pharma launches Fexuprazan tablets for Erosive Esophagitis treatment

Sun Pharmaceutical Industries on Monday said it has introduced a medication for the treatment of Erosive Esophagitis of all grades. The Mumbai-based drug major, in a statement, said it has launched Fexuprazan tablets (40 mg) in India under the brand name Fexuclue, a novel potassium-competitive acid blocker (PCAB). The product is approved as a new treatment for adults with Erosive Esophagitis of all grades, it added. Sun Pharma has obtained rights from South Korea-based Daewoong Pharmaceutical to manufacture and commercialise the medication in India. As per the agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties, it said. "Erosive Esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management. Fexuclue is a best-in-class treatment option with the potential to bridge this gap," Sun Pharma CEO India Business Kirti Ganorkar ...

Biocon, Cipla: Nifty Pharma down 6% as US eyes possible tariffs on sector

Adding to the worries of investors, US is looking for possible tariffs on the pharmaceutical goods

Nifty Pharma jumps 5% as US exempts reciprocal tariff on pharma goods

All 20 Nifty Pharma constituents settled in the green. Among others, Ipca Laboratories was up 4.59 per cent, Lupin was up 4.19 per cent, Cipla was up 3.28 per cent, Sun Pharma was up 3.41 per cent

Sun Pharma, Zydus recall medicines in US over quality concerns: USFDA

Sun Pharma and Zydus Pharmaceuticals are recalling products in the US market due to manufacturing issues, according to the US Food and Drug Administration (USFDA). The New Jersey-based Sun Pharmaceutical Industries, Inc is recalling 9,840 bottles of Morphine Sulfate extended-release tablets for "Failed Dissolution Specifications", the US health regulator stated in its latest Enforcement Report. The company initiated the Class II nationwide (US) recall on February 6, 2025. USFDA stated that Zydus Pharmaceuticals (USA) Inc is recalling a lot of Nelarabine Injection, used in the treatment of certain cancers, in the US. The company is recalling 36,978 vials of Nelarabine Injection in strength of 250mg/50mL, (5mg/mL) for "Failed Impurities/ Degradation Specifications," USFDA stated. The company initiated the Class II recall in February. Zydus is also recalling 1,893 vials of the drug in strength of 250mg/50mL, (5mg/mL). The company initiated the Class II nationwide recall on February

Despite near-term challenges, brokerages remain positive on Sun Pharma

The recent trigger for the stock is the acquisition of US-based Checkpoint Therapeutics

Sun Pharma to acquire US based onco-derma firm Checkpoint for $355 mn

Sun Pharma plans to leverage its global presence to accelerate patient access to this crucial treatment

Sun Pharma to acquire US based Checkpoint Therapeutics for $355 million

The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations

Maruti, Titan: View on stocks that may be impacted by US reciprocal tariffs

The US President Donald Trump has vowed to impose reciprocal tariffs on India and other countries from April 2, 2025 onwards. Here's a technical outlook on Indian stocks that may be impacted.

Stocks to Watch, Feb 21, 2025: Religare Ent, CIE Automotive, TCS, Vedanta

Stocks to Watch, Feb 21, 2025: Here is a list of stocks that could be buzzing in trade today

Sun Pharmaceutical seeks shareholder nod for RPTs worth $1 billion

A key component of the transactions includes a $650 million funding arrangement for its U.S. subsidiary, Sun Pharmaceutical Industries Inc. (SPI Inc.), to support business expansion